Presence of EGF ligand restricts the binding ability of EgB4 nanobody to EGFR extracellular domain
Abstract EgB4 is a nanobody that could facilitate the development of drug–nanobody conjugates or drug delivery in cancer treatment due to its specific binding ability to the EGFR transmembrane protein. More significantly, EgB4 does not hamper the EGFR function and associates with EGFR in both the pr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-86646-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|